The #GFN24 theme, "Economics, health and tobacco harm reduction", has offered an opportunity for diverse programming drawing on varied approaches. Characterising this are Professor Andrzej Fal and Vivian Azer, two presenters from vastly different professional backgrounds, both bringing their unique perspectives to GFN for the very first time.
Firstly, speaking on Thursday 13 June at the opening of #GFN24, is internationally renowned expert in lung health, allergies and public health, Professor Andrzej Fal. The current President of the Polish Society of Public Health, he leads the Department of Allergies, Lung and Internal Diseases at Poland’s National Institute of Medicine, and over the course of a distinguished career, he has published more than 350 papers in his areas of expertise.
Professor Fal’s address, titled ‘Health and economic benefits of tobacco harm reduction’, will examine the impact of different models of policy and use of safer nicotine products and continued combustible tobacco use, on individual and population health. Hosted by Dr. Grzegorz Król, Professor Fal’s address will be followed by a response from Michelle Minton, senior policy analyst at the US-based Reason Foundation, where she specialises in consumer policy and regulatory issues.
On Saturday 15 June, Vivien Azer will deliver her keynote, titled ‘Tobacco harm reduction market influence - past, present, future’. A leading financial analyst and nicotine market specialist, she will be sharing a perspective drawn from her stellar career on Wall Street where, until recently, she was Managing Director and Senior Analyst in Global Beverages, Tobacco and Cannabis at T.D. Cowen. Her coverage of the tobacco and cannabis sectors earned her industry accolades, including a spot on Institutional Investor’s All-America Research Team on several occasions. In 2022, Vivien was selected as one of the most influential names in cannabis on Forbes’ “The Cannabis 42.0” list.
Vivien Azer will discuss the complex factors that prompted and drove initial investment in the field, as well as the potential impacts of regulation or prohibition on future investment patterns. As the first senior US financial analyst to cover the emerging cannabis sector, she will consider whether there are lessons to be learned from its trajectory for the safer nicotine product industry. Hosted by David Sweanor, Adjunct Professor at the Faculty of Law, University of Ottowa, the response will be offered by Jon Fell, former Chief Executive Officer and Partner at the UK-based investment firm, Ash Park Capital.
#GFN24 Conference Director, Jessica Harding, commented that she is excited to bring new voices to the conference to share their expertise on the economic and health impacts of tobacco harm reduction. She continued: “There are tens of millions of people worldwide who already have or could successfully quit smoking by switching to safer nicotine products. At #GFN24, we’ll be asking what is the cost to those individuals, to their families, to the health systems that must care for them, or the economies that must manage without their labour, if poorly drafted regulation pushes them back to combustible tobacco? And to what extent will the future of tobacco harm reduction be decided not by governments, but by the markets and consumer demand for safer products?”
Registration for #GFN24 is open now, and accommodation at the Warsaw Marriott can be booked at a discounted rate until Friday 10 May. In-person attendance is required to participate in the full programme, but selected sessions will be streamed at no cost for registered participants unable to travel. Simultaneous translation into both Spanish and Russian will be available both onsite and online for numerous sessions.
ENDS
Notes to editors
Contact: media@gfn.events
Images and assets: Access a selection of GFN logos, editorial photos from previous events and
profile images for the two keynote speakers discussed in this release until 23/04/24.
Media registration: Media representatives are invited to attend GFN24 and should register here. Please note that there will be a short delay while your application is processed by a member of the GFN Team. Sight of official media accreditation or a supporting letter from your outlet’s editor may be requested.
Dates and location: The Global Forum on Nicotine 2024: Economics, health and tobacco harm reduction (#GFN24) runs from Thursday 13 to Saturday 15 June at the Warsaw Marriott Hotel, Al. Jerozolimskie 65/79, Warsaw 00-697 Poland.
Conference audience: The Global Forum on Nicotine is the only global event that welcomes all stakeholders involved with new and safer nicotine products, including: consumers and consumer advocates, public health experts, policy analysts, parliamentarians and government officials, academics and researchers, product manufacturers and distributors, and media representatives.
Funding: The Global Forum on Nicotine does not receive sponsorship from manufacturers, distributors or retailers of nicotine products including pharmaceutical, vaping and tobacco companies. Conference-supporting organisations endorse the event, but have no financial or administrative involvement in organisation of the event.
Conference organisers: The Global Forum on Nicotine is organised by KAC Communications, a UK-based events company committed to providing a platform for global public health debate, knowledge exchange and networking, underpinned by the principles of inclusiveness and multi-sectoral engagement.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
